Nilamadhab Mishra
Assistant Professor of Internal Medicine - Rheumatology 

B.Sc., 1983 Bhadrak College, India
M.D., 1989 Berhampur University, India 
Clinical Fellowship, 2001, Wake Forest University School of Medicine

Research interests are in the area of Systemic Lupus Erythematosus. This includes epigenetics, chromatin remodeling, transcriptional regulation, gene expression in lupus. He believes that the histone modification circus: balancing acts fundamental to human biology and diseases. He recently demonstrated that histone deacetylase inhibitors such as trichostatin A and/or related compounds suberoylanilide hydroxamic acid (SAHA) are potential candidates for the treatment of human lupus. This is the first compound identified which modulate the expression of several skewed genes that are associated with immunopathogenesis of lupus. His goal is to develop new therapeutic targets for the treatment and prevention of SLE.

Recent Publications (selected):

Mishra N, Brown DR, Olorenshaw IM, Kammer GM. Trichostatin A reverses skewed expression of CD154, IL-10 and IFN-g gene and protein expression in lupus T cells. Proceedings of National Academy of Sciences 2001;98(5):2628-2633.

Mishra N, Reilly C, Brown DR, Ruiz P, Gilkeson G, Kammer GM. Histone deacetylase inhibitors inhibit Th1 and Th2 cytokine gene expression and modulate renal disease in MRL/lpr mice model of lupus. (Submitted)

Mishra N, Brown DR, Kammer GM. Histone deacetylase inhibitors up regulate transforming Growth Factor (TGF-b1) transcription via chromatin remodeling. (Submitted)